The natural history of infantile mitochondrial DNA depletion syndrome due to RRM2B deficiency

Nandaki Keshavan, Jose Abdenur, Glenn Anderson, Zahra Assouline, Giulia Barcia, Lamia Bouhikbar, Anupam Chakrapani, Maureen Cleary, Marta C Cohen, François Feillet, Carl Fratter, Natalie Hauser, Tom Jacques, Amanda Lam, Helen McCullagh, Rahul Phadke, Agnès Rötig, Mark Sharrard, Mariella Simon, Conrad Smith, Ewen W Sommerville, Robert W Taylor, Wyatt W Yue, Shamima Rahman, Nandaki Keshavan, Jose Abdenur, Glenn Anderson, Zahra Assouline, Giulia Barcia, Lamia Bouhikbar, Anupam Chakrapani, Maureen Cleary, Marta C Cohen, François Feillet, Carl Fratter, Natalie Hauser, Tom Jacques, Amanda Lam, Helen McCullagh, Rahul Phadke, Agnès Rötig, Mark Sharrard, Mariella Simon, Conrad Smith, Ewen W Sommerville, Robert W Taylor, Wyatt W Yue, Shamima Rahman

Abstract

Purpose: Mitochondrial DNA (mtDNA) depletion syndrome (MDDS) encompasses a group of genetic disorders of mtDNA maintenance. Mutation of RRM2B is an uncommon cause of infantile-onset encephalomyopathic MDDS. Here we describe the natural history of this disease.

Methods: Multinational series of new genetically confirmed cases from six pediatric centers.

Results: Nine new cases of infantile-onset RRM2B deficiency, and 22 previously published cases comprised a total cohort of 31 patients. Infants presented at a mean of 1.95 months with truncal hypotonia, generalized weakness, and faltering growth. Seizures evolved in 39% at a mean of 3.1 months. Non-neurological manifestations included respiratory distress/failure (58%), renal tubulopathy (55%), sensorineural hearing loss (36%), gastrointestinal disturbance (32%), eye abnormalities (13%), and anemia (13%). Laboratory features included elevated lactate (blood, cerebrospinal fluid (CSF), urine, magnetic resonance (MR), spectroscopy), ragged-red and cytochrome c oxidase-deficient fibers, lipid myopathy, and multiple oxidative phosphorylation enzyme deficiencies in skeletal muscle. Eight new RRM2B variants were identified. Patients with biallelic truncating variants had the worst survival. Overall survival was 29% at 6 months and 16% at 1 year.

Conclusions: Infantile-onset MDDS due to RRM2B deficiency is a severe disorder with characteristic clinical features and extremely poor prognosis. Presently management is supportive as there is no effective treatment. Novel treatments are urgently needed.

Keywords: mitochondrial disease; mtDNA depletion; outcomes; ribonucleotide reductase; treatment.

References

    1. Smith P, Zhou B, Ho N, et al. 2.6 A X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase. Biochemistry. 2009;48:11134–11141.
    1. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature. 2000;404:42–49.
    1. Bourdon A, Minai L, Serre V, et al. Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion. Nat Genet. 2007;39:776–780.
    1. Pontarin G, Fijolek A, Pizzo P, et al. Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage. Proc Natl Acad Sci USA. 2008;105:17801–17806.
    1. Kollberg G, Darin N, Benan K, et al. A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion. Neuromuscul Disord. 2009;19:147–150.
    1. El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013;10:186–198.
    1. Viscomi C, Zeviani M. MtDNA-maintenance defects: syndromes and genes. J Inherit Metab Dis. 2017;40:587–599.
    1. Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nat Rev Neurol. 2019;15:40–52.
    1. Gorman GS, Taylor RW. RRM2B-related mitochondrial disease. In: Adam MP, Ardinger HH, Pagon RA, (eds.) GeneReviews. Seattle, WA: University of Washington; 1993.
    1. Bornstein B, Area E, Flanigan KM, et al. Mitochondrial DNA depletion syndrome due to mutations in the RRM2B gene. Neuromuscul Disord. 2008;18:453–459.
    1. Acham-Roschitz B, Plecko B, Lindbichler F, et al. A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy. Mol Genet Metab. 2009;98:300–304.
    1. Spinazzola A, Invernizzi F, Carrara F, et al. Clinical and molecular features of mitochondrial DNA depletion syndromes. J Inherit Metab Dis. 2009;32:143–158.
    1. Stojanovic V, Mayr JA, Sperl W, Barisic N, Doronjski A, Milak G. Infantile peripheral neuropathy, deafness, and proximal tubulopathy associated with a novel mutation of the RRM2B gene: case study. Croat Med J. 2013;54:579–584.
    1. Pronicka E, Piekutowska-Abramczuk D, Ciara E, et al. New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre. J Transl Med. 2016;14:174.
    1. McCormack SE, Gai X, Place E, Falk MJ. Mitochondrial DNA depletion syndromes presenting in childhood. In: Saneto RP, Parikh S, Cohen BH, (eds.) Mitochondrial case studies. London: Academic Press; 2016. p. 187–198.
    1. Kropach N, Shkalim-Zemer V, Orenstein N, Scheuerman O, Straussberg R. Novel RRM2B mutation and severe mitochondrial DNA depletion: report of 2 cases and review of the literature. Neuropediatrics. 2017;48:456–462.
    1. Tyynismaa H, Ylikallio E, Patel M, Molnar MJ, Haller RG, Suomalainen A. A heterozygous truncating mutation in RRM2B causes autosomal-dominant progressive external ophthalmoplegia with multiple mtDNA deletions. Am J Hum Genet. 2009;85:290–295.
    1. Fratter C, Raman P, Alston CL, et al. RRM2B mutations are frequent in familial PEO with multiple mtDNA deletions. Neurology. 2011;76:2032–2034.
    1. Pitceathly RD, Fassone E, Taanman JW, et al. Kearns–Sayre syndrome caused by defective R1/p53R2 assembly. J Med Genet. 2011;48:610–617.
    1. Takata A, Kato M, Nakamura M, et al. Exome sequencing identifies a novel missense variant in RRM2B associated with autosomal recessive progressive external ophthalmoplegia. Genome Biol. 2011;12:R92.
    1. Pitceathly RD, Smith C, Fratter C, et al. Adults with RRM2B-related mitochondrial disease have distinct clinical and molecular characteristics. Brain. 2012;135(pt 11):3392–3403.
    1. Shaibani A, Shchelochkov OA, Zhang S, et al. Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B. Arch Neurol. 2009;66:1028–1032.
    1. Valencia CA, Wang X, Wang J, et al. Deep sequencing reveals novel genetic variants in children with acute liver failure and tissue evidence of impaired energy metabolism. PLoS ONE. 2016;11:e0156738.
    1. Poulton J, Sewry C, Potter CG, et al. Variation in mitochondrial DNA levels in muscle from normal controls. Is depletion of mtDNA in patients with mitochondrial myopathy a distinct clinical syndrome. J Inherit Metab Dis. 1995;18:4–20.
    1. Mestek-Boukhibar L, Clement E, Jones WD, et al. Rapid paediatric sequencing (RaPS): comprehensive real-life workflow for rapid diagnosis of critically ill children. J Med Genet. 2018;55:721–728.
    1. Nicholls TJ, Nadalutti CA, Motori E, et al. Topoisomerase 3ɑ is required for decatenation and segregation of human mtDNA. Mol Cell. 2018;69:9–23 e26.
    1. Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res. 2005;33:W382–W388.
    1. Rahman S, Poulton J. Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child. 2009;94:3–5.
    1. Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H. Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet. 2003;34:440–445.
    1. Keshavan N, Rahman S. Natural history of mitochondrial disorders: a systematic review. Essays Biochem. 2018;62:423–442.
    1. Garone C, Garcia-Diaz B, Emmanuele V, et al. Deoxypyrimidine monophosphate bypass therapy for thymidine kinase 2 deficiency. EMBO Mol Med. 2014;6:1016–1027.
    1. Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, et al. Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol. 2017;81:641–652.
    1. Pontarin G, Ferraro P, Rampazzo C, et al. Deoxyribonucleotide metabolism in cycling and resting human fibroblasts with a missense mutation in p53R2, a subunit of ribonucleotide reductase. J Biol Chem. 2011;286:11132–11140.
    1. Pontarin G, Ferraro P, Reichard P, Bianchi V. Out of S-phase: shift of subunits for ribonucleotide reduction. Cell Cycle. 2012;11:4099–4100.
    1. Bulst S, Holinski-Feder E, Payne B, et al. In vitro supplementation with deoxynucleoside monophosphates rescues mitochondrial DNA depletion. Mol Genet Metab. 2012;107:95–103.
    1. Larcher V, Craig F, Bhogal K, et al. Making decisions to limit treatment in life-limiting and life-threatening conditions in children: a framework for practice. Arch Dis Child. 2015;100(suppl 2):s3–s23.
    1. Ray S, Brierley J, Bush A, et al. Towards developing an ethical framework for decision making in long-term ventilation in children. Arch Dis Child. 2018;103:1080–1084.
    1. Rahman J, Rahman S. Mitochondrial medicine in the omics era. Lancet. 2018;391:2560–2574.
    1. Horvath R, Kemp JP, Tuppen HA, et al. Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. Brain. 2009;132(pt 11):3165–3174.
    1. Garone C, Taylor RW, Nascimento A, et al. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018;55:515–521.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren